MannKind endocrine news

MannKind reduced headcount by about 100 to about 480 to conserve cash. The cuts came primarily from technical operations, including manufacturing and supply chain. MannKind said it hopes to secure a partner for its lead Afresa by the end of September and that discussions are now "actively under way" with a number of potential big pharma partners. The company submitted an NDA to FDA for Afresa to treat Type I and Type II diabetes in March and expects to submit a regulatory application in Europe in early 2010. Afresa is a dry powder formulation of insulin plus an inhaler (see BioCentury, March 23). ...